Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis

Figure 4 The changes of creatinine clearance (eGFR) during the tenofovir disoproxil fumarate therapy. Of seven patients with increased serum creatinine more than 0.5 mg/dL, three were in compensated group and four were in decompensated group (2.5% vs 7.0%, P < 1.000). There were no statistically significant differences in the changes of creatinine clearance between the decompensated and the compensated group during treatment. LC: Liver cirrhosis.